# Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 Inhibitor

> clinical trial · VERIFIED · 2026-09-01

Status: NOT_YET_RECRUITING · Sponsor: National Heart, Lung, and Blood Institute (NHLBI) · Condition: Chronic Lymphocytic Leukemia

- Company: National Heart, Lung, and Blood Institute (NHLBI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07796373

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.